The inflammatory bowel diseases (IBD) Crohn's disease and ulcerative colitis are debilitating diseases of unknown etiology that affect 1-2 million individuals in the U.S. The current objective of this project is to further define the role that mucosal T cells play in the pathogenesis of IBD. The specific focus is to determine the mediators released by T cells in lesions, and to determine the T cell receptor specificity of lymphocytes in lesions. Previous studies of lymphokine production by IBD T cells have depended on in vitro activation of lymphocytes isolated from enzymatic digests of intestinal tissues, and there is no information regarding lymphokine production by T cells in situ. In current studies RNA was isolated from colonoscopic biopsies from patients with inflammatory bowel disease and noninflammatory controls (colon cancer or suspected cancer). We developed a sensitive method for quantitation of lymphokine mRNA expression in endoscopic biopsies. RNA was extracted from intestinal biopsies, reverse transcribed into cDNA, and amplified by PCR for IL-2. Dilutions of synthetic IL-2 mRNA transcripts that were slightly longer than native IL-2 were added to RNA samples as internal standards. IL-2 mRNA was detectable in as few as 100 activated lymphocytes or about 1 pg of mRNA, and dose response curves showed that there was a quantitative relationship between input mRNA and PCR products over a multiple log range. Using this method, we have found that expression of IL-2 was increased in biopsies of IBD patients who have active inflammation. This is the first demonstration of an abnormal increase in lymphokine expression in IBD. The proposed course will take advantage of this technology to define the T cell mediators expressed in inflammatory lesions and identify the T cell receptors expressed by T cells in IBD lesions. These results may serve as the basis for novel immunotherapies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI000354-08
Application #
3809633
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
8
Fiscal Year
1990
Total Cost
Indirect Cost
City
State
Country
United States
Zip Code
Meng, Guangxun; Zhang, Fuping; Fuss, Ivan et al. (2009) A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity 30:860-74
Yang, Zhiqiong; Fuss, Ivan J; Watanabe, Tomohiro et al. (2007) NOD2 transgenic mice exhibit enhanced MDP-mediated down-regulation of TLR2 responses and resistance to colitis induction. Gastroenterology 133:1510-21
Strober, Warren; Fuss, Ivan; Mannon, Peter (2007) The fundamental basis of inflammatory bowel disease. J Clin Invest 117:514-21
Mannon, Peter J; Fuss, Ivan J; Dill, Susie et al. (2006) Excess IL-12 but not IL-23 accompanies the inflammatory bowel disease associated with common variable immunodeficiency. Gastroenterology 131:748-56
Fuss, Ivan J; Becker, Christoph; Yang, Zhiqiong et al. (2006) Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis 12:9-15
Strober, Warren; Fuss, Ivan J (2006) Experimental models of mucosal inflammation. Adv Exp Med Biol 579:55-97
Leon, Francisco; Contractor, Nikhat; Fuss, Ivan et al. (2006) Antibodies to complement receptor 3 treat established inflammation in murine models of colitis and a novel model of psoriasiform dermatitis. J Immunol 177:6974-82
Watanabe, Tomohiro; Kitani, Atsushi; Murray, Peter J et al. (2006) Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signaling and induction of antigen-specific colitis. Immunity 25:473-85
Strober, Warren; Murray, Peter J; Kitani, Atsushi et al. (2006) Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol 6:9-20
Strober, Warren (2006) Immunology. Unraveling gut inflammation. Science 313:1052-4

Showing the most recent 10 out of 37 publications